Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Hisamoto Kuroda"'
Autor:
Hiroki Nakajima, Sadanori Okada, Takako Mohri, Eiichiro Kanda, Naoyuki Inaba, Yoko Hirasawa, Hiroaki Seino, Hisamoto Kuroda, Toru Hiyoshi, Tetsuji Niiya, Hitoshi Ishii
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 10, Iss 1, Pp 1-11 (2018)
Abstract Background The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they
Externí odkaz:
https://doaj.org/article/ac37bf87a40d4be1a5be0ae3f1d0bbe4
Autor:
Shunichi Murano, Nobuya Fujita, Ken Tomotsune, Minoru Sato, Hisamoto Kuroda, Yasuko Chiba, Yoshihisa Takada, Mihoko Matsumura, Teruo Jojima, Yoshimasa Aso, Isao Usui
Publikováno v:
International Journal of Clinical Practice. 75
AIM We compared the efficacy and safety of insulin degludec/insulin aspart co-formulation (IDegAsp) twice-daily to a free combination of basal insulin degludec and GLP-1 receptor agonist liraglutide (IDeg + Lira) once-daily for patients with inadequa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22fa908e412df581c1cf8b94d814feb6
https://doi.org/10.1111/ijcp.13734
https://doi.org/10.1111/ijcp.13734
Autor:
Nobuya Fujita, Yasuko Chiba, Teruo Jojima, Yoshihisa Takada, Hisamoto Kuroda, Shunichi Murano, Ken Tomotsune, Mihoko Matsumura, Yoshimasa Aso, Minoru Sato, Isao Usui
Aim: We compared the efficacy and safety of insulin degludec/insulin aspart co-formulation (IDegAsp) twice-daily to a free combination of basal insulin degludec and GLP-1 receptor agonist liraglutide (IDeg+Lira) once-daily for patients with inadequat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad0041fad598cfc95e406e7c7cd5bdd1
https://doi.org/10.22541/au.159129005.57065700
https://doi.org/10.22541/au.159129005.57065700
Autor:
Hisamoto Kuroda, Midori Fujishiro, Masahiro Inoue, Motonobu Anai, Hiroaki Seino, Hiroshi Ohashi, Masumi Ai, Toru Kitazawa, Masayo Yamada, Takeshi Inazawa, Hisamitsu Ishihara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b3b98914fa8b44e42bca8b9e7ae7353
https://doi.org/10.1111/dom.14059/v2/response1
https://doi.org/10.1111/dom.14059/v2/response1
Autor:
Nobuya Fujita, Kunihiro Suzuki, Yoshimasa Aso, Yoshihisa Takada, Hisamoto Kuroda, Minoru Sato, Yasuko Chiba, Shunichi Murano
Publikováno v:
Diabetes Research and Clinical Practice. 130:237-243
Insulin degludec (IDeg) is an ultra-long-acting insulin that has a smooth time/action profile over more than 42h. The present study compared the effects of IDeg and insulin glargine (IGlar) on HbA1c reduction and on within-subject day-to-day variabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46467a63601fe56ebf6119ad680aea5
https://doi.org/10.1016/j.diabres.2017.06.007
https://doi.org/10.1016/j.diabres.2017.06.007
Autor:
Motonobu Anai, Toru Kitazawa, Masayo Yamada, Hisamitsu Ishihara, Masahiro Inoue, Hisamoto Kuroda, Hiroaki Seino, Hiroshi Ohashi, Takeshi Inazawa, Midori Fujishiro, Masumi Ai
Publikováno v:
Diabetes Therapy
Background The global pandemic of type 2 diabetes mellitus (T2DM) is an enormous clinical and socioeconomic burden. Biguanides and DPP-4 inhibitors (DPP-4i) are the most commonly used therapies in Japanese T2DM patients. When glycemic control is not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3041ca33f74c7e2b9a1b00d547a68ca4
https://pubmed.ncbi.nlm.nih.gov/30145651
https://pubmed.ncbi.nlm.nih.gov/30145651
Autor:
Toru Hiyoshi, Hirotaka Watada, Hitoshi Ishii, Shimpei Fujimoto, Hideki Nishimura, Masahiko Gosho, Tomoya Mita, Yoshio Fujitani, Toshiki Matsubara, Masumi Ai, Takahisa Hirose, Kiyohito Takahashi, Hisamoto Kuroda, Hiromasa Goto, Hiroaki Satoh, Yosuke Okada
Publikováno v:
Endocrine journal. 65(6)
Treatment-related quality of life (QOL) is an important aspect of diabetes management. However, no studies have compared the influence of dipeptidyl peptidase-4 inhibitors versus alpha-glucosidase inhibitors on treatment-related QOL. This prespecifie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af94fea3d35939bd011f40768a439fab
https://pubmed.ncbi.nlm.nih.gov/29643323
https://pubmed.ncbi.nlm.nih.gov/29643323
Autor:
Hitoshi Ishii, Hiroki Nakajima, Takako Mohri, Toru Hiyoshi, Naoyuki Inaba, Hiroaki Seino, Hisamoto Kuroda, Tetsuji Niiya, Eiichiro Kanda, Yoko Hirasawa, Sadanori Okada
Publikováno v:
Diabetology & Metabolic Syndrome
Diabetology & Metabolic Syndrome, Vol 10, Iss 1, Pp 1-11 (2018)
Diabetology & Metabolic Syndrome, Vol 10, Iss 1, Pp 1-11 (2018)
BackgroundThe benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1612066eaee09ee802d8ea804492dce
https://doi.org/10.1186/s13098-018-0313-x
https://doi.org/10.1186/s13098-018-0313-x
Autor:
Nakajima, Hiroki, Sadanori Okada, Mohri, Takako, Kanda, Eiichiro, Inaba, Naoyuki, Hirasawa, Yoko, Seino, Hiroaki, Hisamoto Kuroda, Hiyoshi, Toru, Niiya, Tetsuji, Ishii, Hitoshi
Additional file 1. List of the 29 medical institutions participating in the study. The data on this file include the names of the 29 participating medical institutions in this multi-center study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e5259dc901e0ee9a562911c7ad7c881
Autor:
Hiromasa Goto, Tomoya Mita, Yoshio Fujitani, Shimpei Fujimoto, Kiyohito Takahashi, Hiroaki Satoh, Takahisa Hirose, Toru Hiyoshi, Masumi Ai, Yosuke Okada, Hideki Nishimura, Hisamoto Kuroda, Toshiki Matsubara, Masahiko Gosho, Hitoshi Ishii, Hirotaka Watada
Publikováno v:
Endocrine Journal; 2018, Vol. 65 Issue 6, p657-668, 12p